JP2012512887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512887A5 JP2012512887A5 JP2011542420A JP2011542420A JP2012512887A5 JP 2012512887 A5 JP2012512887 A5 JP 2012512887A5 JP 2011542420 A JP2011542420 A JP 2011542420A JP 2011542420 A JP2011542420 A JP 2011542420A JP 2012512887 A5 JP2012512887 A5 JP 2012512887A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- ylcarbamoyl
- thiazol
- tetrahydroquinolin
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 39
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 38
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 32
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 30
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000004429 atom Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- -1 morpholino, pyrrolidinyl Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 15
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 15
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 15
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 230000005494 condensation Effects 0.000 claims description 10
- 238000009833 condensation Methods 0.000 claims description 10
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000004419 alkynylene group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 4
- 239000005973 Carvone Substances 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical group O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 2
- GUARKFCLDYLQOJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[4-(dimethylamino)phenoxy]propoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(N(C)C)=CC=C1OCCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O GUARKFCLDYLQOJ-UHFFFAOYSA-N 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940081066 picolinic acid Drugs 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 claims 1
- SSVPVQYXJINXMD-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydroindol-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCC3=CC=2)=N1 SSVPVQYXJINXMD-UHFFFAOYSA-N 0.000 claims 1
- MPBQJXNTYAFDCG-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=N1 MPBQJXNTYAFDCG-UHFFFAOYSA-N 0.000 claims 1
- ACWUWQFNFCECSG-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(3-phenoxypropyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1CCCOC1=CC=CC=C1 ACWUWQFNFCECSG-UHFFFAOYSA-N 0.000 claims 1
- ZHZAYMPWFBZMHS-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-ethoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OCC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 ZHZAYMPWFBZMHS-UHFFFAOYSA-N 0.000 claims 1
- GYMYCTAHQRHBRX-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-fluorophenoxy)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1OC1=CC=C(F)C=C1 GYMYCTAHQRHBRX-UHFFFAOYSA-N 0.000 claims 1
- IUZOFLCDLUXADA-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-methoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 IUZOFLCDLUXADA-UHFFFAOYSA-N 0.000 claims 1
- BLYXYYLADZOEON-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-methoxyphenyl)-n,n-dimethyl-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C(=O)N(C)C)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 BLYXYYLADZOEON-UHFFFAOYSA-N 0.000 claims 1
- ATYICJLSTAZWCH-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-phenylphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1C(C=C1)=CC=C1C1=CC=CC=C1 ATYICJLSTAZWCH-UHFFFAOYSA-N 0.000 claims 1
- PHOMBWBRLPRDRL-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-propan-2-yloxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 PHOMBWBRLPRDRL-UHFFFAOYSA-N 0.000 claims 1
- PVCRLFNDYPWXRE-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-pyrazolo[3,4-d]pyrimidin-1-ylphenoxy)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C3=NC(=C(S3)OC=3C=CC(=CC=3)N3C4=NC=NC=C4C=N3)C(=O)O)=NC2=C1 PVCRLFNDYPWXRE-UHFFFAOYSA-N 0.000 claims 1
- DTCSCHOGNLBRFF-NTCAYCPXSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[(e)-2-phenylethenyl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1\C=C\C1=CC=CC=C1 DTCSCHOGNLBRFF-NTCAYCPXSA-N 0.000 claims 1
- JAUZXPWFDMIDMP-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[3-(4-tert-butylphenoxy)propyl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 JAUZXPWFDMIDMP-UHFFFAOYSA-N 0.000 claims 1
- GTWRWEWSFSCPBX-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(OCCCC2=C(N=C(S2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 GTWRWEWSFSCPBX-UHFFFAOYSA-N 0.000 claims 1
- BFJVFGNQPLQUFT-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[3-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 BFJVFGNQPLQUFT-UHFFFAOYSA-N 0.000 claims 1
- XBBJQSQPJIYQNM-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-phenoxy-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1OC1=CC=CC=C1 XBBJQSQPJIYQNM-UHFFFAOYSA-N 0.000 claims 1
- YVGIJURHOZQQNX-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-phenyl-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1C1=CC=CC=C1 YVGIJURHOZQQNX-UHFFFAOYSA-N 0.000 claims 1
- HASSMSDDEAAJPW-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=N1 HASSMSDDEAAJPW-UHFFFAOYSA-N 0.000 claims 1
- ZZKMAEDLBJHEQI-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(3-fluorophenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1C1=CC=CC(F)=C1 ZZKMAEDLBJHEQI-UHFFFAOYSA-N 0.000 claims 1
- QUHHOHYGJVFKDL-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(3-methoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound COC1=CC=CC(C2=C(N=C(S2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)C(O)=O)=C1 QUHHOHYGJVFKDL-UHFFFAOYSA-N 0.000 claims 1
- SOLJRIFANYSREL-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(3-pyridin-4-ylsulfanylpropyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1CCCSC1=CC=NC=C1 SOLJRIFANYSREL-UHFFFAOYSA-N 0.000 claims 1
- LOHJTCRXLYLPCQ-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-carboxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1C1=CC=C(C(O)=O)C=C1 LOHJTCRXLYLPCQ-UHFFFAOYSA-N 0.000 claims 1
- ONXODEQOLDFBQK-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-fluorophenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1C1=CC=C(F)C=C1 ONXODEQOLDFBQK-UHFFFAOYSA-N 0.000 claims 1
- LVKBROXLISEWPG-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-methoxyphenoxy)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1OC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 LVKBROXLISEWPG-UHFFFAOYSA-N 0.000 claims 1
- GMVXPHSJOARWRE-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-methoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 GMVXPHSJOARWRE-UHFFFAOYSA-N 0.000 claims 1
- SDMNMUQLECLURJ-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-phenylbutyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1CCCCC1=CC=CC=C1 SDMNMUQLECLURJ-UHFFFAOYSA-N 0.000 claims 1
- XSVMITITZADKSV-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 XSVMITITZADKSV-UHFFFAOYSA-N 0.000 claims 1
- HWSFZVVKRJNAAM-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-[methyl(2-phenoxyethyl)amino]-1,3-thiazole-4-carboxylic acid Chemical compound S1C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=NC(C(O)=O)=C1N(C)CCOC1=CC=CC=C1 HWSFZVVKRJNAAM-UHFFFAOYSA-N 0.000 claims 1
- BYMHFFYJCHILSC-UHFFFAOYSA-N 2-[4-(quinolin-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4N=C5C=CC=CC5=CC=4)CCOC3=CC=2)=N1 BYMHFFYJCHILSC-UHFFFAOYSA-N 0.000 claims 1
- QJSGRRAKWYNXIA-UHFFFAOYSA-N 3-(3-phenylpropoxy)-6-[4-(pyrazolo[1,5-a]pyridin-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC4=NN5C=CC=CC5=C4)CCOC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 QJSGRRAKWYNXIA-UHFFFAOYSA-N 0.000 claims 1
- AYINEXHHTDRALS-UHFFFAOYSA-N 3-[2-(3-aminophenoxy)ethoxy]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound NC1=CC=CC(OCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 AYINEXHHTDRALS-UHFFFAOYSA-N 0.000 claims 1
- RCVLLTPEOVNERE-UHFFFAOYSA-N 3-[2-[4-(aminomethyl)phenoxy]ethoxy]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O RCVLLTPEOVNERE-UHFFFAOYSA-N 0.000 claims 1
- LSULJKVPDWRHOH-UHFFFAOYSA-N 3-[3-(1,3-benzodioxol-5-yloxy)propoxy]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)OCCCOC=3C=C4OCOC4=CC=3)C(=O)O)=NC2=C1 LSULJKVPDWRHOH-UHFFFAOYSA-N 0.000 claims 1
- CGWQYFHTZRBUAD-UHFFFAOYSA-N 3-[3-[(3-aminophenoxy)methyl]phenyl]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound NC1=CC=CC(OCC=2C=C(C=CC=2)C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 CGWQYFHTZRBUAD-UHFFFAOYSA-N 0.000 claims 1
- VDKULKVSOILPLQ-UHFFFAOYSA-N 3-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]pyridine-2-carboxylic acid Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N1C2=C(OCC1)C=CC(=C2)C=1C(=NC=CC=1)C(=O)O VDKULKVSOILPLQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- XNAZSUQOXPFRCI-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-[1-(1,3-thiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC=CN=4)CCCC3=CC=2)S1 XNAZSUQOXPFRCI-UHFFFAOYSA-N 0.000 claims 1
- NFBBOKMAQZIDEG-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-[1-[(4-methyl-1,3-thiazol-2-yl)carbamoyl]-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC=C(C)N=4)CCCC3=CC=2)S1 NFBBOKMAQZIDEG-UHFFFAOYSA-N 0.000 claims 1
- KSTDEFWREQYWLG-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-[1-[(5-methyl-1,3-thiazol-2-yl)carbamoyl]-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC(C)=CN=4)CCCC3=CC=2)S1 KSTDEFWREQYWLG-UHFFFAOYSA-N 0.000 claims 1
- CCIXRCPQCKVEBP-UHFFFAOYSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 CCIXRCPQCKVEBP-UHFFFAOYSA-N 0.000 claims 1
- GXQIXHPTOZPFNJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(1h-indol-5-yl)pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)C=3C=C4C=CNC4=CC=3)C(=O)O)=NC2=C1 GXQIXHPTOZPFNJ-UHFFFAOYSA-N 0.000 claims 1
- YVYJHOMCXCHVPR-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-methyl-4-oxo-1h-quinazolin-6-yl)pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C3=CC=C(C(=N3)C(O)=O)C3=CC=C4N=C(NC(=O)C4=C3)C)=NC2=C1 YVYJHOMCXCHVPR-UHFFFAOYSA-N 0.000 claims 1
- BVHQJPPKPSCFCT-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-methylpropoxy)pyridine-2-carboxylic acid Chemical compound N1=C(C(O)=O)C(OCC(C)C)=CC=C1C1=CC=C(CCCN2C(=O)NC=3SC4=CC=CC=C4N=3)C2=C1 BVHQJPPKPSCFCT-UHFFFAOYSA-N 0.000 claims 1
- CAOYRZRBLLJSBC-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-phenoxyethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCOC1=CC=CC=C1 CAOYRZRBLLJSBC-UHFFFAOYSA-N 0.000 claims 1
- OQQWYANTFMGUKE-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-phenylethynyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1C#CC1=CC=CC=C1 OQQWYANTFMGUKE-UHFFFAOYSA-N 0.000 claims 1
- NLQXXKDTSHGAQP-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-pyridin-2-ylethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCC1=CC=CC=N1 NLQXXKDTSHGAQP-UHFFFAOYSA-N 0.000 claims 1
- OUNKSAYPXCSZFA-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-pyridin-4-ylethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCC1=CC=NC=C1 OUNKSAYPXCSZFA-UHFFFAOYSA-N 0.000 claims 1
- XPXYZCVVFSWPNG-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-methylsulfonylphenyl)pyridine-2-carboxylic acid Chemical compound CS(=O)(=O)C1=CC=CC(C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 XPXYZCVVFSWPNG-UHFFFAOYSA-N 0.000 claims 1
- HJHOIRJAPDOTOL-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-morpholin-4-ylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCCN1CCOCC1 HJHOIRJAPDOTOL-UHFFFAOYSA-N 0.000 claims 1
- ACSSINBYLJIAAG-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-phenylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 ACSSINBYLJIAAG-UHFFFAOYSA-N 0.000 claims 1
- KQDWYTVCGULVGO-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-quinolin-8-yloxypropoxy)pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)OCCCOC=3C4=NC=CC=C4C=CC=3)C(=O)O)=NC2=C1 KQDWYTVCGULVGO-UHFFFAOYSA-N 0.000 claims 1
- JNWWJUXWTIXBKQ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(4-tert-butylphenyl)pyridine-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O JNWWJUXWTIXBKQ-UHFFFAOYSA-N 0.000 claims 1
- UCGPCAWDOQTKSX-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(cyclobutylmethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCC1CCC1 UCGPCAWDOQTKSX-UHFFFAOYSA-N 0.000 claims 1
- SUALKLTVTLZBAP-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[(4-phenylphenyl)methoxy]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCC(C=C1)=CC=C1C1=CC=CC=C1 SUALKLTVTLZBAP-UHFFFAOYSA-N 0.000 claims 1
- CNWFABUNOZPXRG-JXMROGBWSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[(e)-2-(4-fluorophenyl)ethenyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1\C=C\C1=CC=C(F)C=C1 CNWFABUNOZPXRG-JXMROGBWSA-N 0.000 claims 1
- QNLSEXFKDAEUHM-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-(2-oxopyrrolidin-1-yl)ethoxy]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCN1CCCC1=O QNLSEXFKDAEUHM-UHFFFAOYSA-N 0.000 claims 1
- ZCJFOMBPZOLDAM-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[3-(dimethylamino)phenoxy]ethoxy]pyridine-2-carboxylic acid Chemical compound CN(C)C1=CC=CC(OCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 ZCJFOMBPZOLDAM-UHFFFAOYSA-N 0.000 claims 1
- VMBDJGUXZKQXPY-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]ethoxy]pyridine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(OCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 VMBDJGUXZKQXPY-UHFFFAOYSA-N 0.000 claims 1
- VWDRTFKKWLAYQF-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]ethoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1OCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O VWDRTFKKWLAYQF-UHFFFAOYSA-N 0.000 claims 1
- IGRYCCZPZKOHII-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[[4-(dimethylamino)phenyl]methylamino]ethoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(N(C)C)=CC=C1CNCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O IGRYCCZPZKOHII-UHFFFAOYSA-N 0.000 claims 1
- YLQNUEFFPHWWJJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-(4-chlorophenyl)propoxy]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCCC1=CC=C(Cl)C=C1 YLQNUEFFPHWWJJ-UHFFFAOYSA-N 0.000 claims 1
- FVAHMCDFRIMIDJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[3-(dimethylamino)phenoxy]propoxy]pyridine-2-carboxylic acid Chemical compound CN(C)C1=CC=CC(OCCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 FVAHMCDFRIMIDJ-UHFFFAOYSA-N 0.000 claims 1
- NVPQUZOPZFEGPK-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[4-(dimethylamino)phenyl]propoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(N(C)C)=CC=C1CCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O NVPQUZOPZFEGPK-UHFFFAOYSA-N 0.000 claims 1
- UGYWSMFACSGFSA-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]methyl]phenyl]pyridine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(OCC=2C=C(C=CC=2)C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 UGYWSMFACSGFSA-UHFFFAOYSA-N 0.000 claims 1
- XOIHGIKDINPDRX-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]pyridine-2-carboxylic acid Chemical compound C1CN(C)CCN1C1=CC=C(C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)C=N1 XOIHGIKDINPDRX-UHFFFAOYSA-N 0.000 claims 1
- VOWYYLBWRUSDMW-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-butoxypyridine-2-carboxylic acid Chemical compound N1=C(C(O)=O)C(OCCCC)=CC=C1C1=CC=C(CCCN2C(=O)NC=3SC4=CC=CC=C4N=3)C2=C1 VOWYYLBWRUSDMW-UHFFFAOYSA-N 0.000 claims 1
- WYPAZEMYKBFKQE-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-hydroxypyridine-2-carboxylic acid Chemical compound C1=C(O)C(C(=O)O)=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=C1 WYPAZEMYKBFKQE-UHFFFAOYSA-N 0.000 claims 1
- HQDGISOEKNLNCW-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-naphthalen-2-ylpyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)C=3C=C4C=CC=CC4=CC=3)C(=O)O)=NC2=C1 HQDGISOEKNLNCW-UHFFFAOYSA-N 0.000 claims 1
- WWSKHLBGFIOZBT-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-phenylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1C1=CC=CC=C1 WWSKHLBGFIOZBT-UHFFFAOYSA-N 0.000 claims 1
- XBXFJADFUJRUBK-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=N1 XBXFJADFUJRUBK-UHFFFAOYSA-N 0.000 claims 1
- OYACQQIAQVEEMQ-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-1-methyl-2,3-dihydroquinoxalin-6-yl]-3-(3-phenoxypropoxy)pyridine-2-carboxylic acid Chemical compound C=1C=C2N(C)CCN(C(=O)NC=3SC4=CC=CC=C4N=3)C2=CC=1C(N=C1C(O)=O)=CC=C1OCCCOC1=CC=CC=C1 OYACQQIAQVEEMQ-UHFFFAOYSA-N 0.000 claims 1
- HRNHYKJWRGNWJS-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-1-methyl-2,3-dihydroquinoxalin-6-yl]pyridine-2-carboxylic acid Chemical compound C=1C=C2N(C)CCN(C(=O)NC=3SC4=CC=CC=C4N=3)C2=CC=1C1=CC=CC(C(O)=O)=N1 HRNHYKJWRGNWJS-UHFFFAOYSA-N 0.000 claims 1
- HMVBMFMZLAKSHW-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-3-(3-phenoxypropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCOC1=CC=CC=C1 HMVBMFMZLAKSHW-UHFFFAOYSA-N 0.000 claims 1
- YKVDZNKXELHTAX-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-3-(3-phenylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 YKVDZNKXELHTAX-UHFFFAOYSA-N 0.000 claims 1
- LWATZYLDPRGOCZ-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-3-(3-pyridin-4-ylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCC1=CC=NC=C1 LWATZYLDPRGOCZ-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010061825 Duodenal neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- NGTGDMNCIHYUOY-UHFFFAOYSA-N N-(1,3-benzothiazol-2-yl)-7-[5-(1-benzylpyrazol-4-yl)-6-methylpyridin-2-yl]-3,4-dihydro-2H-quinoline-1-carboxamide Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N1CCCC2=CC=C(C=C12)C1=CC=C(C(=N1)C)C=1C=NN(C=1)CC1=CC=CC=C1 NGTGDMNCIHYUOY-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- MPXONXSGCYHXEC-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)CCC2=CC=C(C=C2)F Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)CCC2=CC=C(C=C2)F MPXONXSGCYHXEC-UHFFFAOYSA-N 0.000 claims 1
- YEZWLRFUWBTVKJ-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)OC2=CC=C(C=C2)N(C)C Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)OC2=CC=C(C=C2)N(C)C YEZWLRFUWBTVKJ-UHFFFAOYSA-N 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000000702 anti-platelet effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010039 central nervous system leukemia Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000000312 duodenum cancer Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- KEBGAEIUKRGVKA-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-6-[6-(methylsulfonylcarbamoyl)-5-(3-phenylpropoxy)pyridin-2-yl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound CS(=O)(=O)NC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 KEBGAEIUKRGVKA-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 201000011294 ureter cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13947908P | 2008-12-19 | 2008-12-19 | |
| US61/139,479 | 2008-12-19 | ||
| PCT/US2009/068400 WO2010080478A1 (en) | 2008-12-19 | 2009-12-17 | Compounds and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512887A JP2012512887A (ja) | 2012-06-07 |
| JP2012512887A5 true JP2012512887A5 (OSRAM) | 2014-10-09 |
| JP5683484B2 JP5683484B2 (ja) | 2015-03-11 |
Family
ID=42316717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542420A Active JP5683484B2 (ja) | 2008-12-19 | 2009-12-17 | 化合物と使用法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8114893B2 (OSRAM) |
| EP (1) | EP2376085B1 (OSRAM) |
| JP (1) | JP5683484B2 (OSRAM) |
| KR (1) | KR101633532B1 (OSRAM) |
| CN (1) | CN102325531B (OSRAM) |
| AU (1) | AU2009335818A1 (OSRAM) |
| BR (1) | BRPI0918337A2 (OSRAM) |
| CA (1) | CA2747161C (OSRAM) |
| CO (1) | CO6390110A2 (OSRAM) |
| CR (1) | CR20110389A (OSRAM) |
| DO (1) | DOP2011000198A (OSRAM) |
| EC (1) | ECSP11011214A (OSRAM) |
| ES (1) | ES2462715T3 (OSRAM) |
| IL (1) | IL213547A0 (OSRAM) |
| MX (1) | MX2011006514A (OSRAM) |
| NZ (1) | NZ593536A (OSRAM) |
| PE (1) | PE20120305A1 (OSRAM) |
| RU (1) | RU2561109C2 (OSRAM) |
| SG (1) | SG172266A1 (OSRAM) |
| WO (1) | WO2010080478A1 (OSRAM) |
| ZA (1) | ZA201104463B (OSRAM) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2134685T3 (en) | 2007-04-16 | 2015-12-07 | Abbvie Inc | 7-unsubstituted indole derivatives as MCL-1 inhibitors |
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| AU2009335843A1 (en) * | 2008-12-19 | 2011-07-21 | Abbvie Inc. | Heterocyclic compounds and methods of use |
| PE20120305A1 (es) * | 2008-12-19 | 2012-04-09 | Abbott Lab | Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| ES2659763T3 (es) | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103958508B (zh) * | 2011-10-14 | 2019-02-12 | 艾伯维公司 | 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂 |
| KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| WO2014179734A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of Michigan | Deuterated amlexanox |
| RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| TR201810944T4 (tr) | 2013-10-25 | 2018-08-27 | Novartis Ag | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. |
| WO2015112801A1 (en) * | 2014-01-24 | 2015-07-30 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| WO2015153959A2 (en) | 2014-04-04 | 2015-10-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
| EP3708170A1 (en) | 2014-05-05 | 2020-09-16 | BioVentures, LLC | Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents |
| WO2016007532A1 (en) * | 2014-07-08 | 2016-01-14 | Dow Agrosciences Llc | Process for the preparation of 3-hydroxypicolinic acids |
| EP3177144A4 (en) | 2014-07-22 | 2018-01-24 | Bioventures, LLC. | Compositions and methods for selectively depleting senescent cells |
| JP6707517B2 (ja) * | 2014-07-28 | 2020-06-10 | メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ | 金属錯体 |
| ES2756748T3 (es) | 2014-10-03 | 2020-04-27 | Novartis Ag | Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4 |
| BR112017012342A2 (pt) * | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| EP3407974A4 (en) | 2016-01-29 | 2019-08-28 | The Regents Of The University Of Michigan | Amlexanox Analogs |
| NZ757763A (en) | 2016-03-28 | 2025-07-25 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| EP3445452A4 (en) | 2016-04-21 | 2019-10-30 | BioVentures, LLC | COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CN108251377B (zh) * | 2018-01-16 | 2021-08-27 | 内蒙古大学 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
| CN112105360B (zh) | 2018-01-22 | 2024-01-30 | 生物风险投资有限责任公司 | 用于癌症治疗的bcl-2蛋白降解剂 |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| EP3705109A1 (en) | 2019-03-05 | 2020-09-09 | Greenaltech, S.L. | Carotenoids in the treatment of senescence-related diseases |
| WO2021213380A1 (zh) * | 2020-04-20 | 2021-10-28 | 深圳市塔吉瑞生物医药有限公司 | 吡嗪取代的烟酰胺的固体形式及其制备和用途 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| US20230270816A1 (en) | 2020-07-06 | 2023-08-31 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| IL303048A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| KR20230170644A (ko) | 2021-02-02 | 2023-12-19 | 르 라보레또레 쎄르비에르 | 선택적 bcl-xl protac 화합물 및 사용 방법 |
| TW202345857A (zh) * | 2022-03-08 | 2023-12-01 | 美商昂科斯克塞爾醫療有限責任公司 | 他波司他之穩定調配物 |
| CN118974033A (zh) * | 2022-03-31 | 2024-11-15 | 百济神州有限公司 | Bcl-xL抑制剂 |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| US20250339547A1 (en) | 2022-05-20 | 2025-11-06 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CR20240553A (es) | 2022-05-20 | 2025-05-02 | Servier Lab | Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5265280A (en) | 1975-11-26 | 1977-05-30 | Squibb & Sons Inc | Benzoxadinones and their production |
| DE19929785A1 (de) * | 1999-06-29 | 2001-01-04 | Bayer Ag | Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung |
| CN1422262A (zh) * | 2000-02-07 | 2003-06-04 | 艾博特股份有限两合公司 | 2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用 |
| JP4403305B2 (ja) * | 2001-09-03 | 2010-01-27 | 武田薬品工業株式会社 | １，３−ベンゾチアジノン誘導体および用途 |
| EP1424336A4 (en) | 2001-09-03 | 2004-11-10 | Takeda Chemical Industries Ltd | 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE |
| CA2470721C (en) | 2001-12-14 | 2011-07-12 | Alcon, Inc. | Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| CA2620818A1 (en) | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| DK2050749T3 (en) * | 2006-08-08 | 2018-01-08 | Chugai Pharmaceutical Co Ltd | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF |
| KR101511074B1 (ko) | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| DK2134685T3 (en) | 2007-04-16 | 2015-12-07 | Abbvie Inc | 7-unsubstituted indole derivatives as MCL-1 inhibitors |
| CN101842362A (zh) * | 2007-09-27 | 2010-09-22 | 沃尔特及伊莱萨霍尔医学研究院 | 苯并噻唑化合物 |
| EP2341052A4 (en) | 2008-09-05 | 2011-10-12 | Shionogi & Co | RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT |
| AU2009335843A1 (en) | 2008-12-19 | 2011-07-21 | Abbvie Inc. | Heterocyclic compounds and methods of use |
| PE20120305A1 (es) | 2008-12-19 | 2012-04-09 | Abbott Lab | Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl |
-
2009
- 2009-12-17 PE PE2011001249A patent/PE20120305A1/es not_active Application Discontinuation
- 2009-12-17 NZ NZ593536A patent/NZ593536A/xx not_active IP Right Cessation
- 2009-12-17 ES ES09837907.6T patent/ES2462715T3/es active Active
- 2009-12-17 RU RU2011129789/04A patent/RU2561109C2/ru active
- 2009-12-17 CA CA2747161A patent/CA2747161C/en active Active
- 2009-12-17 AU AU2009335818A patent/AU2009335818A1/en not_active Abandoned
- 2009-12-17 EP EP09837907.6A patent/EP2376085B1/en active Active
- 2009-12-17 CR CR20110389A patent/CR20110389A/es unknown
- 2009-12-17 SG SG2011044922A patent/SG172266A1/en unknown
- 2009-12-17 KR KR1020117016719A patent/KR101633532B1/ko not_active Expired - Fee Related
- 2009-12-17 JP JP2011542420A patent/JP5683484B2/ja active Active
- 2009-12-17 MX MX2011006514A patent/MX2011006514A/es active IP Right Grant
- 2009-12-17 US US12/641,063 patent/US8114893B2/en active Active
- 2009-12-17 CN CN200980157162.3A patent/CN102325531B/zh active Active
- 2009-12-17 BR BRPI0918337A patent/BRPI0918337A2/pt not_active IP Right Cessation
- 2009-12-17 WO PCT/US2009/068400 patent/WO2010080478A1/en not_active Ceased
-
2011
- 2011-06-14 IL IL213547A patent/IL213547A0/en unknown
- 2011-06-15 ZA ZA2011/04463A patent/ZA201104463B/en unknown
- 2011-06-17 DO DO2011000198A patent/DOP2011000198A/es unknown
- 2011-07-01 CO CO11082793A patent/CO6390110A2/es active IP Right Grant
- 2011-07-18 EC EC2011011214A patent/ECSP11011214A/es unknown
-
2012
- 2012-01-10 US US13/347,364 patent/US8518970B2/en active Active
-
2013
- 2013-06-27 US US13/929,701 patent/US9067928B2/en active Active - Reinstated
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512887A5 (OSRAM) | ||
| JP6968141B2 (ja) | 新規ｕｌｋ１阻害剤およびそれを使用する方法 | |
| AU2016309833B2 (en) | Pharmaceutical composition and application replacing quinolone derivative, pharmaceutical acceptable salt, or stereoisomer | |
| AU2005205915B2 (en) | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases | |
| JP2021073269A (ja) | 細胞代謝過程の阻害剤 | |
| US20050222171A1 (en) | Organic compounds | |
| CN116723843A (zh) | 用于治疗和/或预防癌症的sos1抑制剂的药物组合 | |
| JP2011507854A5 (OSRAM) | ||
| TW202122387A (zh) | Mta協同性之prmt5抑制劑 | |
| PT1511730E (pt) | Derivados de diaril-ureia úteis para o tratamento de doenças dependentes de proteína quinase | |
| JP2010540458A5 (OSRAM) | ||
| AU2020307631B9 (en) | Casein kinase 1ε inhibitor, pharmaceutical composition and application thereof | |
| JP2010508324A (ja) | プロテインキナーゼモジュレーターとしての３−アミノカルボニル置換縮合ピラゾロ誘導体 | |
| JP2009535335A5 (OSRAM) | ||
| CN102264725A (zh) | 蛋白激酶抑制剂 | |
| CN105481862B (zh) | Flt3激酶的新型抑制剂及其用途 | |
| EA024194B1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| CN101460500A (zh) | 作为激酶抑制剂的3-取代的N-(芳基-或杂芳基)-吡唑并[1,5-a]嘧啶 | |
| CN104936956A (zh) | 氨基取代的异噻唑 | |
| EP2582675B1 (en) | Compounds for treating proliferative disorders | |
| CN103214481B (zh) | 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
| JP2006511498A5 (OSRAM) | ||
| CN107459521A (zh) | Flt3激酶的新型抑制剂及其用途 | |
| KR101937529B1 (ko) | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
| CN105050602B (zh) | 作为pi3激酶抑制剂的吡啶化合物 |